[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 50.16.107.222. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Viewpoint
ONLINE FIRST
September 5, 2012

Preexposure Prophylaxis for HIV Infection

Author Affiliations

Author Affiliation: Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.

JAMA. 2012;308(9):865-866. doi:10.1001/jama.2012.9885

On July 16, 2012, the US Food and Drug Administration (FDA) approved a daily oral antiretroviral drug to reduce the risk of sexual acquisition of human immunodeficiency virus (HIV) infection by uninfected adults.1,2 Emtricitabine/tenofovir disoproxil fumarate (marketed by Gilead as Truvada) contains 2 nucleoside analogue HIV-1 reverse transcriptase inhibitors. Initially approved in 2004 to treat HIV infection in combination with other antiretroviral medications in people 12 years of age and older, emtricitabine/tenofovir costs about $13 900 a year in the United States for a year of treatment.

First Page Preview View Large
First page PDF preview
First page PDF preview
×